Literature DB >> 23261904

Use of bifidobacterial specific terminal restriction fragment length polymorphisms to complement next generation sequence profiling of infant gut communities.

Zachery T Lewis1, Nicholas A Bokulich, Karen M Kalanetra, Santiago Ruiz-Moyano, Mark A Underwood, David A Mills.   

Abstract

Bifidobacteria are intestinal anaerobes often associated with gut health. Specific bifidobacterial species are particularly common in the gastrointestinal tract of breast-fed infants. Current short read next-generation sequencing approaches to profile fecal microbial ecologies do not discriminate bifidobacteria to the species level. Here we describe a low-cost terminal restriction fragment length polymorphism (TRFLP) procedure to distinguish between the common infant-associated bifidobacterial species. An empirical database of TRF sizes was created from both common reference strains and well-identified isolates from infant feces. Species-specific quantitative PCR validated bifidobacterial-specific TRFLP profiles from infant feces. These results indicate that bifidobacterial-specific TRFLP is a useful method to monitor intestinal bifidobacterial populations from infant fecal samples. When used alongside next generation sequencing methods that detect broader population levels at lower resolution, this high-throughput, low-cost tool can help clarify the role of bifidobacteria in health and disease.
Copyright © 2012. Published by Elsevier Ltd.

Entities:  

Mesh:

Year:  2012        PMID: 23261904      PMCID: PMC4764513          DOI: 10.1016/j.anaerobe.2012.12.005

Source DB:  PubMed          Journal:  Anaerobe        ISSN: 1075-9964            Impact factor:   3.331


  42 in total

Review 1.  Genomics and ecological overview of the genus Bifidobacterium.

Authors:  Francesca Turroni; Douwe van Sinderen; Marco Ventura
Journal:  Int J Food Microbiol       Date:  2010-12-28       Impact factor: 5.277

2.  Greengenes, a chimera-checked 16S rRNA gene database and workbench compatible with ARB.

Authors:  T Z DeSantis; P Hugenholtz; N Larsen; M Rojas; E L Brodie; K Keller; T Huber; D Dalevi; P Hu; G L Andersen
Journal:  Appl Environ Microbiol       Date:  2006-07       Impact factor: 4.792

3.  Exploring the diversity of the bifidobacterial population in the human intestinal tract.

Authors:  Francesca Turroni; Elena Foroni; Paola Pizzetti; Vanessa Giubellini; Angela Ribbera; Paolo Merusi; Patrizio Cagnasso; Barbara Bizzarri; Gian Luigi de'Angelis; Fergus Shanahan; Douwe van Sinderen; Marco Ventura
Journal:  Appl Environ Microbiol       Date:  2009-01-23       Impact factor: 4.792

4.  Evaluation of PCR-generated chimeras, mutations, and heteroduplexes with 16S rRNA gene-based cloning.

Authors:  X Qiu; L Wu; H Huang; P E McDonel; A V Palumbo; J M Tiedje; J Zhou
Journal:  Appl Environ Microbiol       Date:  2001-02       Impact factor: 4.792

5.  Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR.

Authors:  Erja Malinen; Teemu Rinttilä; Kajsa Kajander; Jaana Mättö; Anna Kassinen; Lotta Krogius; Maria Saarela; Riitta Korpela; Airi Palva
Journal:  Am J Gastroenterol       Date:  2005-02       Impact factor: 10.864

6.  Culture-independent analysis of fecal microbiota in infants, with special reference to Bifidobacterium species.

Authors:  Shinji Sakata; Toshiki Tonooka; Shinobu Ishizeki; Masaaki Takada; Mitsuo Sakamoto; Masafumi Fukuyama; Yoshimi Benno
Journal:  FEMS Microbiol Lett       Date:  2005-02-15       Impact factor: 2.742

7.  Distinct gut microbiota in southeastern African and northern European infants.

Authors:  Łukasz Grześkowiak; Maria Carmen Collado; Charles Mangani; Kenneth Maleta; Kirsi Laitinen; Per Ashorn; Erika Isolauri; Seppo Salminen
Journal:  J Pediatr Gastroenterol Nutr       Date:  2012-06       Impact factor: 2.839

8.  Brewhouse-resident microbiota are responsible for multi-stage fermentation of American coolship ale.

Authors:  Nicholas A Bokulich; Charles W Bamforth; David A Mills
Journal:  PLoS One       Date:  2012-04-18       Impact factor: 3.240

9.  Barcoded pyrosequencing reveals that consumption of galactooligosaccharides results in a highly specific bifidogenic response in humans.

Authors:  Lauren M G Davis; Inés Martínez; Jens Walter; Caitlin Goin; Robert W Hutkins
Journal:  PLoS One       Date:  2011-09-26       Impact factor: 3.240

10.  MiCA: a web-based tool for the analysis of microbial communities based on terminal-restriction fragment length polymorphisms of 16S and 18S rRNA genes.

Authors:  Conrad Shyu; Terry Soule; Stephen J Bent; James A Foster; Larry J Forney
Journal:  Microb Ecol       Date:  2007-04-04       Impact factor: 4.192

View more
  15 in total

1.  Identification of Oligosaccharides in Feces of Breast-fed Infants and Their Correlation with the Gut Microbial Community.

Authors:  Jasmine C C Davis; Sarah M Totten; Julie O Huang; Sadaf Nagshbandi; Nina Kirmiz; Daniel A Garrido; Zachery T Lewis; Lauren D Wu; Jennifer T Smilowitz; J Bruce German; David A Mills; Carlito B Lebrilla
Journal:  Mol Cell Proteomics       Date:  2016-07-19       Impact factor: 5.911

2.  A comparison of two probiotic strains of bifidobacteria in premature infants.

Authors:  Mark A Underwood; Karen M Kalanetra; Nicholas A Bokulich; Zachery T Lewis; Majid Mirmiran; Daniel J Tancredi; David A Mills
Journal:  J Pediatr       Date:  2013-08-29       Impact factor: 4.406

3.  Bifidobacterium Abundance in Early Infancy and Vaccine Response at 2 Years of Age.

Authors:  M Nazmul Huda; Shaikh M Ahmad; M Jahangir Alam; Afsana Khanam; Karen M Kalanetra; Diana H Taft; Rubhana Raqib; Mark A Underwood; David A Mills; Charles B Stephensen
Journal:  Pediatrics       Date:  2019-02       Impact factor: 7.124

Review 4.  Technicalities and Glitches of Terminal Restriction Fragment Length Polymorphism (T-RFLP).

Authors:  Om Prakash; Prashant K Pandey; Girish J Kulkarni; Kiran N Mahale; Yogesh S Shouche
Journal:  Indian J Microbiol       Date:  2014-03-09       Impact factor: 2.461

5.  Stool microbiota and vaccine responses of infants.

Authors:  M Nazmul Huda; Zachery Lewis; Karen M Kalanetra; Mamunur Rashid; Shaikh M Ahmad; Rubhana Raqib; Firdausi Qadri; Mark A Underwood; David A Mills; Charles B Stephensen
Journal:  Pediatrics       Date:  2014-07-07       Impact factor: 7.124

6.  Maternal fucosyltransferase 2 status affects the gut bifidobacterial communities of breastfed infants.

Authors:  Zachery T Lewis; Sarah M Totten; Jennifer T Smilowitz; Mina Popovic; Evan Parker; Danielle G Lemay; Maxwell L Van Tassell; Michael J Miller; Yong-Su Jin; J Bruce German; Carlito B Lebrilla; David A Mills
Journal:  Microbiome       Date:  2015-04-10       Impact factor: 14.650

7.  The Fecal Microbial Community of Breast-fed Infants from Armenia and Georgia.

Authors:  Zachery T Lewis; Ketevan Sidamonidze; Vardan Tsaturyan; David Tsereteli; Nika Khachidze; Astghik Pepoyan; Ekaterine Zhgenti; Liana Tevzadze; Anahit Manvelyan; Marine Balayan; Paata Imnadze; Tamas Torok; Danielle G Lemay; David A Mills
Journal:  Sci Rep       Date:  2017-02-02       Impact factor: 4.379

8.  Assessment of Bifidobacterium Species Using groEL Gene on the Basis of Illumina MiSeq High-Throughput Sequencing.

Authors:  Lujun Hu; Wenwei Lu; Linlin Wang; Mingluo Pan; Hao Zhang; Jianxin Zhao; Wei Chen
Journal:  Genes (Basel)       Date:  2017-11-21       Impact factor: 4.096

9.  Validating bifidobacterial species and subspecies identity in commercial probiotic products.

Authors:  Zachery T Lewis; Guy Shani; Chad F Masarweh; Mina Popovic; Steve A Frese; David A Sela; Mark A Underwood; David A Mills
Journal:  Pediatr Res       Date:  2015-11-16       Impact factor: 3.756

10.  Matrix Effects on the Delivery Efficacy of Bifidobacterium animalis subsp. lactis BB-12 on Fecal Microbiota, Gut Transit Time, and Short-Chain Fatty Acids in Healthy Young Adults.

Authors:  Zhaoyong Ba; Yujin Lee; Huicui Meng; Penny M Kris-Etherton; Connie J Rogers; Zachery T Lewis; David A Mills; Emily J Furumoto; M Laura Rolon; Jennifer A Fleming; Robert F Roberts
Journal:  mSphere       Date:  2021-07-07       Impact factor: 4.389

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.